NASDAQ:ITMN - InterMune Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Receive ITMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ITMN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:ITMN
CUSIP45884X10
WebN/A
Phone+1-415-4662200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

InterMune (NASDAQ:ITMN) Frequently Asked Questions

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Has InterMune been receiving favorable news coverage?

Press coverage about ITMN stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. InterMune earned a news and rumor sentiment score of 0.20 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.48 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for InterMune.

How do I buy shares of InterMune?

Shares of ITMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact InterMune?

InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.


MarketBeat Community Rating for InterMune (NASDAQ ITMN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe ITMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.